Last reviewed · How we verify
Myozyme
At a glance
| Generic name | Myozyme |
|---|---|
| Also known as | Alglucosidase alfa, alglucosidase alfa |
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Biologic |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
| Annual revenue | 1100 |
Approved indications
- Lysosomal alpha-1,4-glucosidase deficiency - infantile onset
Common side effects
Key clinical trials
- PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) (PHASE1)
- A Global Prospective Observational Registry of Patients With Pompe Disease
- A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (PHASE2)
- Pompe Pregnancy Sub-Registry
- Developing a Management Approach for Patients With "Late-Onset" Pompe Disease
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PHASE3)
- Expanded Access for ATB200/AT2221 for the Treatment of IOPD
- Drug-drug Interaction Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |